Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Post time 1 hour(s) ago

Lancet

. IF: 88.5Q1
2026 Jun 20;407(10547):2542-2553.
doi: 10.1016/S0140-6736(26)00974-8. Epub 2026 Jun 1.
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study Lin Shen 1, Xiaotian Zhang 2, Ke Ji 3, Linzhi Lu 4, Quan Wang 5, Quanlin Guan 6, Su Yan 7, Yanbing Zhou 8, Yan Yang 9, Zhibin Huo 10, Jun You 11, Yi Ba 12, Yingjiang Ye 13, Ye Chen 14, Shubin Wang 15, Guoqing Lv 16, Jingdong Zhang 17, Xuhui Hu 18, Futang Yang 18, Haoyu Yu 18, Jing Li 18, Qingyu Wang 18, Jun Zhu 18, Jiafu Ji 19; ASTRUM-006 Study Group

Collaborators, Affiliations Expand

[Elsevier] Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study